Insiders Trades
BB
Belite Bio, Inc Stock: price and insider trades · United States
US·Mcap US$6.1B
Belite Bio, Inc: what insiders have been doing
Belite Bio, Inc is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 9 insiders published 158 filings.
No insider bought on the market over the period, while 5 insiders filed 151 sales totalling €32.0M. The totals exclude 13 filings filed without an amount. Biggest ticket of the year: €1.8M, sold by Lin Yu-Hsin and made public on 9 September 2026 (0.030% of market cap).
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 158 filings here. Our records for Belite Bio, Inc go back to 2026, with no purchases and 151 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 20-F puts net income at -77.6 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
158
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€32M
151 ops. · all time
Who traded when
BuySaleMata Nathan L.79 sales
Hao-Yuan Chuang25 sales
Lin Yu-Hsin25 sales
Hendrik Peter Scholl21 sales
Chen Wan-Shan1 sale
Analyst consensus: bullish or bearish?
Analysts rate Belite Bio, Inc Strong Buy (bullish), based on 9 analysts. Average price target: US$228.89.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$152.62
Analyst consensus
9 analystsStrong buy
US$185.00Target US$228.89(+50%)US$303.00
Income statement
EBITDA-US$77.1M
Net income-US$77.6M0.0% margin
Valuation
PER (forward)67.5x
P/Book7.9x
Beta-1.23
Balance sheet & cash
Market capUS$6.1B
Total debtUS$429k
Free Cash Flow-US$37.2M
Profitability & ownership
ROE-22.1%
ROA-15.7%
% insiders43.6%
% institutions24.3%
Last declaration on 5 October 2026
Declarations158 total
200 shares@ US$163.6250.0005% mcap39.6% of flowAmerican depositary shareSEC:0001193125-26-414643:0
24 shares@ US$164.64080.0001% mcap4.8% of flowAmerican depositary shareSEC:0001193125-26-414643:1
120 shares@ US$165.49350.0003% mcap24.0% of flowAmerican depositary shareSEC:0001193125-26-414643:2
50 shares@ US$166.43680.0001% mcap10.1% of flowAmerican depositary shareSEC:0001193125-26-414643:3
78 shares@ US$167.58760.0002% mcap15.8% of flowAmerican depositary shareSEC:0001193125-26-414643:4
12 shares@ US$168.21170.0000% mcap2.4% of flowAmerican depositary shareSEC:0001193125-26-414643:5
14 shares@ US$169.360.0000% mcap2.9% of flowAmerican depositary shareSEC:0001193125-26-414643:6
2 shares@ US$170.020.0000% mcap0.4% of flowAmerican depositary shareSEC:0001193125-26-414643:7
4,000 shares@ US$169.820.010% mcap100.0% of flowAmerican Depositary Shares, each representing one ordinary shareSEC144:0001968582-26-001037
1,633 shares@ US$180.15970.0042% mcap2.1% of flowAmerican depositary shareSEC:0001193125-26-386790:0
2,000 shares@ US$181.05330.0052% mcap2.6% of flowAmerican depositary shareSEC:0001193125-26-386790:1
2,000 shares@ US$182.49260.0052% mcap2.6% of flowAmerican depositary shareSEC:0001193125-26-386790:2
3,759 shares@ US$183.26660.0099% mcap4.9% of flowAmerican depositary shareSEC:0001193125-26-386790:3
3,569 shares@ US$184.57370.0095% mcap4.7% of flowAmerican depositary shareSEC:0001193125-26-386790:4
3,872 shares@ US$185.28090.010% mcap5.1% of flowAmerican depositary shareSEC:0001193125-26-386790:5
4,600 shares@ US$186.3450.012% mcap6.1% of flowAmerican depositary shareSEC:0001193125-26-386790:6
3,900 shares@ US$187.16450.010% mcap5.2% of flowAmerican depositary shareSEC:0001193125-26-386790:7
1,900 shares@ US$188.58840.0051% mcap2.6% of flowAmerican depositary shareSEC:0001193125-26-386790:8
6,200 shares@ US$189.22440.017% mcap8.4% of flowAmerican depositary shareSEC:0001193125-26-386790:9
1,800 shares@ US$190.63310.0049% mcap2.5% of flowAmerican depositary shareSEC:0001193125-26-386790:10
6,200 shares@ US$191.08930.017% mcap8.5% of flowAmerican depositary shareSEC:0001193125-26-386790:11
3,398 shares@ US$192.40380.0094% mcap4.7% of flowAmerican depositary shareSEC:0001193125-26-386790:12
4,602 shares@ US$193.11760.013% mcap6.4% of flowAmerican depositary shareSEC:0001193125-26-386790:13
2,200 shares@ US$194.27910.0061% mcap3.1% of flowAmerican depositary shareSEC:0001193125-26-386790:14
4,120 shares@ US$195.60410.012% mcap5.8% of flowAmerican depositary shareSEC:0001193125-26-386790:15
25 of 158 declarations
About Belite Bio, Inc
Belite Bio, Inc is a company listed on XNAS, focused on developing treatments for metabolic diseases and eye disorders. It emphasizes innovation in the biotechnology sector.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
